Dean Wilkie
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Angiogenesis and VEGF in Cancer, Protease and Inhibitor Mechanisms, Peptidase Inhibition and Analysis, Lung Cancer Treatments and Mutations
Most-Cited Works
- → BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis(2004)4,006 cited
- → Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5(2006)1,531 cited
- → Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models(2006)463 cited
- → Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma(2007)260 cited
- → BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models(2013)254 cited
- → Antitumor activity of sorafenib in FLT3-driven leukemic cells(2007)166 cited
- → JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production(2012)134 cited
- → Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946)(2016)113 cited
- → Morphological and structural characteristics of the proximal femur in human and rat(1997)99 cited
- → Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model(2009)68 cited